ArticleScientific reports2025
Analgesic and anti-inflammatory potential of Ficus Palmata Forssk.: an In-vitro and In-vivo approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ficus virens in neurotherapeutics: bridging ethnomedicinal evidence with Nrf2/Keap1 and neuroinflammatory mechanisms.Molecular biology reports · 2026Review
- Isolation of 3β-Hydroxylupenal From Ceriops decandra Leaves and Evaluation of In Vivo Analgesic and Anti-Inflammatory Effects Supported by Molecular Docking.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ficus palmata (F. palmata) is one of the prominent shrubs that has antioxidant and anti-inflammatory potential and belongs to the family Moraceae. The current study aimed to evaluate the anti-inflammatory and analgesic potential of its aerial parts. The cyclooxygenase enzyme inhibition activity and a human red blood cell (HRBC) membrane stability assay were used to evaluate the in-vitro anti-inflammatory potential of F. palmata ethanolic extract. The in-vivo anti-inflammatory activity was evaluated by the carrageenan-induced paw oedema test, and the analgesic potential by the tail-flick test, acetic acid-induced writhing models, hot plate test, and formalin-induced analgesia, along with measurement of the levels of inflammatory cytokines (IL-6 and TNF-α) in rat serum and histopathological findings. The extract showed in-vitro anti-inflammatory activity through the inhibition of cyclooxygenase (COX) enzymes such as COX-2 at 89.54% and COX-1 at 72.07%, and HRBC membrane stability at 58.8% with 800 μg/mL. In-vivo studies, Fp. EtOH exhibited significant anti-inflammatory (carrageenan-induced paw oedema model), analgesic (hot plate test, tail-flick test, acetic acid-induced writhing and formalin-induced analgesia) responses at the doses 200, 300, and 400 mg/kg. The result demonstrated that the Fp. EtOH at a dosage of 400 mg/kg body weight exhibited efficacy comparable to that of the diclofenac sodium (standard) treatments employed in these models. Histopathological examination of the left hind paw demonstrated that Fp. EtOH effectively reduced paw inflammation, inhibited pannus development and mitigated bone degradation comparable to that of diclofenac sodium. Measurement of inflammatory cytokines (TNF-α and IL-6) and pathological findings were also done. The anti-inflammatory and analgesic activity of F. palmata was supported by results from both in-vitro and in-vivo studies. These findings suggest that F. palmata could be a promising candidate for further research as a natural remedy for inflammation and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.